Intra-individual variations of fasting plasma lipids, apolipoproteins and postprandial lipemia in familial combined hyperlipidemia compared to controls

Clinica Chimica Acta

Volumn 328, Issue 1-2, 2003, Pages 139-145

  Delawi, D ^a   Meijssen, S ^a   Castro Cabezas, M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Apolipoproteins; Atherosclerosis; Familial combined hyperlipidemia; Postprandial lipemia; Triglycerides

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL COMBINED HYPERLIPIDEMIA; FEMALE; GENDER; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0037306834     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(02)00420-5     Document Type: Article

References (40)

1. Goldstein J.L., Schrott H.G., Hazzard W.R., Bierman E.L., Motulsky A.G. Hyperlipidemia in coronary heart disease: Part II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J. Clin. Invest. 52:1973;1544-1568.
2. Rose H.G., Kranz P., Weinstock M., Juliano J., Haft J.I. Inheritance of combined hyperlipoproteinemia: evidence for a new lipoprotein phenotype. Am. J. Cardiol. 54:1973;148-160.
3. Castro Cabezas M., De Bruin T.W., Erkelens D.W. Familial combined hyperlipidaemia. Neth. J. Med. 1973-1991(40):1992;83-95.
4. Pitkanen O.P., Nuutila P., Raitakari O.T., Porkka K., Iida H., Nuotio I.et al. Coronary flow reserve in young men with familial combined hyperlipidemia. Circulation. 99(130):1999;1678-1684.
5. Nikkila E.A., Aro A. Family study of serum lipids and lipoproteins in coronary heart-disease. Lancet. 1:1973;954-959.
6. Rose H.G., Kranz P., Weinstock M., Juliano J., Haft J.I. Inheritance of combined hyperlipoproteinemia: evidence for a new lipoprotein phenotype. Am. J. Med. 54:1973;148-160.
7. Voors-Pette Chr., de Bruin T.W.A. Excess coronary heart disease in familial combined hyperlipidemia, in relation to genetic factors and central obesity. Atherosclerosis. 157:2001;481-489.
8. Ribalta J., La Ville A.E., Vallve J.C., Humphries S., Turner P.R., Masana L. A variation in the apolipoprotein C-III gene is associated with an increased number of circulating VLDL and IDL particles in familial combined hyperlipidemia. J. Lipid Res. 38:1997;1061-1069.
9. Pajukanta P, Terwilliger JD, Perola M, Hiekkalinna T, et al. Genomewide scan for familial combined hyperlipidemia genes in finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels. Am. J. Hum. Genet. 64:1453-1463.
10. Aouizerat B.E., Allayee H., Cantor R.M.et al. A genome scan for familial combined hyperlipidemia reveals evidence of linkage with a locus on chromosome 11. Am. J. Hum. Genet. 65:1999;397-412.
11. Cortner J.A., Coates P.M., Le N.A.et al. Kinetics of chylomicron remnant clearance in normal and in hyperlipoproteinemic subjects. J. Lipid Res. 28:1987;195-206.
12. Janus E.D., Nicoll A.M., Turner P.R., Magill P., Lewis B. Kinetic bases of the primary hyperlipidaemias: studies of apolipoprotein B turnover in genetically defined subjects. Eur. J. Clin. Invest. 10:1980;161-172.
13. Chait A., Albers J.J., Brunzell J.D. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridaemia. Eur. J. Clin. Invest. 10:1980;17-22.
14. Castro Cabezas M., De Bruin T.W., De Valk H.W., Shoulders C.C., Jansen H., Erkelens D.W. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J. Clin. Invest. 92:1993;160-168.
15. Genest J., Sniderman A., Cianflone K. Hyperapobetalipoproteinemia. Plasma lipoprotein responses to oral fat load. Arteriosclerosis. 6:1986;297-304.
16. Ascaso J.F., Merchante A., Lorente R.I., Real J.T., Martinez-Valls J., Carmena R. A study of insulin resistance using the minimal model in nondiabetic familial combined hyperlipidemic patients. Metabolism. 47:1998;508-513.
17. Aitman T.J., Godsland I.F., Farren B., Crook D., Wong H.J., Scott J. Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 17:1997;748-754.
18. Karjalainen L., Pihlajamaki J., Karhapaa P., Laakso M. Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemia? Arterioscler. Thromb. Vasc. Biol. 18:1998;1548-1553.
19. Meijssen S., Castro Cabezas M., Twickler T.B., Jansen H., Erkelens D.W. In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. J. Lipid Res. 41:2000;1096-1102.
20. Babirak S.P., Brown B.G., Brunzell J.D. Familial combined hyperlipidemia and abnormal lipoprotein lipase. Arterioscler. Thromb. 12:1992;1176-1183.
21. Yang W.S., Nevin D.N., Iwasaki L.et al. Regulatory mutations in the human lipoprotein lipase gene in patients with familial combined hyperlipidemia and coronary artery disease. J. Lipid Res. 37:1996;2627-2637.
22. Brunzell J.D., Albers J.J., Chait A., Grundy M., Groszek E., Mcdonald G.B. Plasma lipoprotein in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J. Lipid Res. 24:1983;147-155.
23. Bookstein L., Gidding S.S., Donovan M., Smith F.A. Day-to-day variability of serum cholesterol, triglycerides, and high-density lipoprotein cholesterol levels. Arch. Intern. Med. 150:1990;1653-1657.
24. Kuo P.T., Carson J.C. Dietary fats and the diurnal serum triglyceride levels in man. J. Clin. Invest. 38:1959;1384-1393.
25. McNeely M.J., Edwards K.L., Marcovina S.M., Brunzell J.D., Motulsky A.G., Austin M.A. Lipoprotein and apolipoprotein abnormalities in familial combined hyperlipidemia: a 20-year prospective study. Atherosclerosis. 159:2001;471-481.
26. Schectman G., Hoffmann R.G. A history of hypercholesterolemia influences cholesterol measurements. Arch. Intern. Med. 148:1988;1169-1171.
27. Hetland M.L., Haarbo J., Christiansen C. One measurement of serum total cholesterol is enough to predict future levels in healthy postmenopausal women. Am. J. Med. 92:1992;25-28.
28. Castro Cabezas M., Halkes C.J.M., Meijssen S., Van Oostrom A.J.H.H.M., Erkelens D.W. Diurnal triglyceride profiles: a novel technique to study triglyceride changes. Atherosclerosis. 155(1):2001;219-228.
29. Van Oostrom A.J.H.H.M., Castro Cabezas M., Ribalta J., Twickler Th.B., Remijnse T.A., Erkelens D.W. Diurnal triglyceride profiles in healthy normolipidemic male subjects are associated to insulin sensitivity, body composition and diet. Eur. J. Clin. Invest. 30:2000;964-971.
30. Luley C., Ronquist G., Reuter W.et al. Point-of-care testing of triglycerides: evaluation of the accutrend triglycerides system. Clin. Chem. 46:2000;287-291.
31. Halkes C.J.M., Castro Cabezas M., van Wijk J.P.H., Erkelens D.W. Gender differences in diurnal triglyceridemia in lean and overweight subjects. Int. J. Obes. 25:2001;1767-1774.
32. Van Wijk J.P.H., Castro Cabezas M., Halkes C.J.M., Erkelens D.W. Effects of different nutrient intakes on daytime triacylglycerolemia in healthy, normolipemic, free-living men. Am. J. Clin. Nutr. 74:2001;171-178.
33. Moses R.G., Calvert D., Storlien L.H. Evaluation of the Accutrend GCT with respect to triglyceride monitoring. Diabetes Care. 19:1996;1305-1306.
34. Castro Cabezas M., de Bruin T.W.A., Kock L.A.W., Erkelens D.W. Postprandial apolipoprotein B100 and apo B48 in Familial Combined Hyperlipidemia before and after reduction of fasting plasma triglycerides. Eur. J. Clin. Invest. 24:1994;669-678.
35. Kissebah A.H., Alfarsi S., Evans D.J. Low density lipoprotein metabolism in familial combined hyperlipidemia. Mechanism of the multiple lipoprotein phenotypic expression. Arteriosclerosis. 4:1984;614-624.
36. Gravholt C.H., Holck P., Nyholm B., Christiansen E., Erlandsen M., Schmitz O. No seasonal variation of insulin sensitivity and glucose effectiveness in men. Metabolism. 49(1):2000;32-38.
37. Purnell J.Q., Kahn S., Schwartz R.S., Brunzell J.D. Relationship of insulin sensitivity and apoB levels to intra-abdominal fat in subjects with familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 21:2001;567-572.
38. Ascaso J., Lorente R., Merchante A., Real J., Priego A., Carmena R. Insulin resistance in patients with familial combined hyperlipidemia and coronary artery disease. Am. J. Cardiol. 80:1997;484-487.
39. Karjalainen L., Pihlajamäki J., Karhapää P., Laakso M. Impaired insulin-stimulated glucose oxidation and free fatty acid suppression in patients with familial combined hyperlipidemia: a precursor defect for dyslipidemias? Arterioscler. Thromb. Vasc. Biol. 18:1998;1548-1553.
40. Sinderman A.D., Ribalta J., Castro Cabezas M. How should FCHL be defined and how should we think about its metabolic bases? Nutr. Metab. Cardiovasc. Dis. 11:2001;259-273.